![]() ![]() The paper concluded that lecanemab treatment would improve health and humanistic (quality of life) outcomes and reduce economic burden for patients and caregivers in early AD. when the societal cost of the disease is large with substantial impacts on caregivers, such as AD. A modified societal perspective at $200,000 WTP threshold per QALY gained is used in the U.S. payer perspective was $18,709 to $35,678 ($19,710 to $37,351 for societal perspective) at the willingness-to-pay (WTP) threshold of $100,000 to $200,000 per QALY gained, respectively. The model estimated that the annual value of lecanemab for the U.S. The mean duration of lecanemab treatment in this simulation was 3.91 years. Lecanemab+SoC (standard of care**) was predicted to result in a gain of 0.61 quality-adjusted life-years*** (QALY)s and a decrease in total non-treatment costs of $6,263 per person from the healthcare payer perspective (Societal perspective: 0.64 QALYs gain and $7,451 decrease) compared to the SoC for patients with early AD who have confirmed presence of amyloid pathology. This model-based simulation was conducted using the results of the Phase 3 Clarity AD study evaluating the efficacy and safety of lecanemab for early AD with confirmed amyloid pathology as well as published literature. was used to inform the development of "Eisai's Approach to Pricing for LEQEMBI™ (lecanemab), a Treatment for Early Alzheimer's disease, Sets forth Our Concept of "Societal Value of Medicine" in Relation to "Price of Medicine" that was described in our press release issued on Janu(Japan Standard Time). The findings of this academic paper about the societal value of lecanemab in the U.S. While the healthcare payer perspective focuses on direct care costs (e.g., outpatient and inpatient services, medications, intervention costs, nursing home and home healthcare services), the societal perspective further considers societal costs (e.g., productivity loss and informal care costs). brand name: LEQEMBI™) in people living with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) using data from the Phase 3 clinical study, Clarity AD by applying a validated disease simulation model, AD Archimedes Condition Event (AD ACE) model 1,2,3 from the healthcare payer and societal perspectives in the United States, in the peer-reviewed journal Neurology and Therapy. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced the publication of updated results from an evaluation estimating the societal value of anti-amyloid-beta (Aβ) protofibril* antibody lecanemab (generic name, U.S. ![]() EISAI PUBLISHES SOCIETAL VALUE OF LECANEMAB USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |